1. Home
  2. DNUT vs VOR Comparison

DNUT vs VOR Comparison

Compare DNUT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Krispy Kreme Inc.

DNUT

Krispy Kreme Inc.

HOLD

Current Price

$3.32

Market Cap

585.5M

ML Signal

HOLD

Logo Vor Biopharma Inc.

VOR

Vor Biopharma Inc.

HOLD

Current Price

$15.97

Market Cap

755.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DNUT
VOR
Founded
1937
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Food Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
585.5M
755.7M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DNUT
VOR
Price
$3.32
$15.97
Analyst Decision
Buy
Buy
Analyst Count
6
10
Target Price
$4.72
$45.44
AVG Volume (30 Days)
1.8M
1.2M
Earning Date
05-07-2026
05-13-2026
Dividend Yield
1.05%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,522,616,000.00
N/A
Revenue This Year
$0.55
N/A
Revenue Next Year
$3.59
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.58
$0.13
52 Week High
$5.73
$49.95

Technical Indicators

Market Signals
Indicator
DNUT
VOR
Relative Strength Index (RSI) 46.90 54.63
Support Level $3.17 $11.38
Resistance Level $3.50 $16.88
Average True Range (ATR) 0.16 1.62
MACD -0.01 0.07
Stochastic Oscillator 36.34 52.41

Price Performance

Historical Comparison
DNUT
VOR

About DNUT Krispy Kreme Inc.

Krispy Kreme Inc is a sweet-treat brand company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in-mouth experience. It operates through its network of fresh Doughnut Shops, partnerships with retailers, and a growing e-commerce and delivery business. The company conducts its business through the following three reported segments: U.S., which includes all operations in the United States; International, which includes operations in the U.K., Ireland, Australia, New Zealand, Canada, Japan, and Mexico; and Market Development, which includes franchise operations world-wide. It derives maximum revenue from the U.S. segment.

About VOR Vor Biopharma Inc.

Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.

Share on Social Networks: